FSPKF
Fisher & Paykel Healthcare Corporation Limited
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
24.55
▼ 0.76 (3.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
25.31
Day high
24.55
Day low
24.55
Volume
1.20K
Market cap
$14.42B
P/E (TTM)
52.23
52W range
19.01 – 25.69
Trailing performance
Returnvs SPY
1W
+3.10%
+4.4%
1M
+10.24%
+7.0%
3M
+23.16%
+20.8%
6M
+14.52%
+2.7%
YTD
+31.41%
+19.5%
1Y
+26.49%
+6.4%
3Y
+71.01%
-3.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FSPKF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
21.43M
Total on file
Fundamentals
Market cap$14.42B
Enterprise value$14.54B
Revenue (TTM)$2.31B
Gross profit$1.47B
EBITDA$759.40M
Net income$468.50M
EPS (TTM)$0.47
Free cash flow$399.41M
Total cash$461.10M
Total debt$146.10M
Book value / share$2.15
Shares outstanding587.29M
Float585.02M
Short % of float—
Dividend yield1.17%
Beta (5Y)0.89
Valuation & profitability ratios
Trailing P/E52.23
Forward P/E—
PEG ratio43.70
Price / sales—
Price / book11.44
EV / revenue6.30
EV / EBITDA19.15
Gross margin63.69%
Operating margin28.72%
Profit margin20.29%
Return on equity23.39%
Return on assets14.72%
Debt / equity6.91
Current ratio2.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.31B | $1.28B | $1.76B | $1.59B | +80.3% |
| Operating revenue | $2.31B | $1.28B | $1.76B | $1.59B | +80.3% |
| Cost of revenue | $838.30M | $750.10M | $698.40M | $642.70M | +11.8% |
| Gross profit | $1.47B | $530.20M | $1.06B | $945.90M | +177.3% |
| Research & development | $235.50M | $226.90M | $198.20M | $174.30M | +3.8% |
| Selling, general & admin | $598.20M | $534.40M | $492.80M | $431.90M | +11.9% |
| Total operating expense | $992.30M | $901.20M | $805.30M | $705.20M | +10.1% |
| Operating income | $477.80M | -$371.00M | $254.40M | $240.70M | +228.8% |
| Net interest income | -$2.10M | -$6.80M | -$14.90M | -$4.10M | +69.1% |
| Pre-tax income | $631.50M | $503.30M | $235.70M | $328.00M | +25.5% |
| Tax provision | $163.00M | $126.10M | $103.10M | $77.70M | +29.3% |
| Net income | $468.50M | $377.20M | $132.60M | $250.30M | +24.2% |
| Net income to common | $468.50M | $377.20M | $132.60M | $250.30M | +24.2% |
| Basic EPS | 0.80 | 0.64 | 0.23 | 0.43 | +23.9% |
| Diluted EPS | 0.79 | 0.64 | 0.23 | 0.43 | +24.1% |
| EBIT | $641.80M | $514.40M | $253.90M | $334.70M | +24.8% |
| EBITDA | $800.40M | $654.30M | $368.20M | $433.70M | +22.3% |
| Basic shares | 586.93M | 585.54M | 581.97M | 578.14M | +0.2% |
| Diluted shares | 590.79M | 590.30M | 586.73M | 582.09M | +0.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $461.10M | $264.50M | $82.00M | $121.00M | — | +74.3% |
| Cash & short-term investments | $461.10M | $264.50M | $82.00M | $121.00M | — | +74.3% |
| Accounts receivable | $291.50M | $267.30M | $223.00M | $184.50M | — | +9.1% |
| Inventory | $327.30M | $342.90M | $320.40M | $365.80M | — | -4.5% |
| Total current assets | $1.15B | $935.40M | $704.90M | $774.20M | — | +23.2% |
| Property, plant & equipment | $1.41B | $1.34B | $1.34B | $1.15B | — | +5.1% |
| Goodwill & intangibles | $72.70M | $82.10M | $88.40M | $85.60M | — | -11.4% |
| Total assets | $2.85B | $2.55B | $2.28B | $2.20B | — | +11.9% |
| Total current liabilities | $497.80M | $500.40M | $385.00M | $289.80M | — | -0.5% |
| Current debt | $7.30M | $64.00M | $78.50M | $4.20M | — | -88.6% |
| Long-term debt | $52.50M | — | $35.70M | $79.10M | $63.00M | — |
| Total debt | $146.10M | $153.30M | $189.10M | $145.80M | — | -4.7% |
| Total liabilities | $738.20M | $660.40M | $522.60M | $451.10M | — | +11.8% |
| Retained earnings | $1.44B | $1.23B | $1.09B | $1.20B | — | +17.6% |
| Shareholder equity | $2.12B | $1.89B | $1.76B | $1.75B | — | +11.9% |
| Working capital | $654.40M | $435.00M | $319.90M | $484.40M | — | +50.4% |
| Net tangible assets | $2.04B | $1.81B | $1.67B | $1.67B | — | +13.0% |
| Shares issued | 587.28M | 583.54M | 583.96M | 579.22M | — | +0.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$195.20M | -$103.00M | -$339.00M | -$211.30M | -89.5% |
| Investing cash flow | -$195.20M | -$103.00M | -$339.00M | -$11.30M | -89.5% |
| Dividends paid | -$252.30M | -$195.90M | -$145.50M | -$195.70M | -28.8% |
| Financing cash flow | -$276.70M | -$268.20M | -$128.70M | -$197.10M | -3.2% |
| Free cash flow | $468.00M | $445.60M | $90.60M | $26.90M | +5.0% |
| End cash position | $453.80M | $260.20M | $80.90M | $116.80M | +74.4% |
| Line item | 2025-03-31 | YoY |
|---|---|---|
| Total revenue | $1.28B | |
| Operating revenue | $1.28B | |
| Cost of revenue | $750.10M | |
| Gross profit | $530.20M | |
| Research & development | $226.90M | |
| Selling, general & admin | $534.40M | |
| Total operating expense | $901.20M | |
| Operating income | -$371.00M | |
| Net interest income | -$6.80M | |
| Pre-tax income | $503.30M | |
| Tax provision | $126.10M | |
| Net income | $377.20M | |
| Net income to common | $377.20M | |
| Basic EPS | 0.64 | |
| Diluted EPS | 0.64 | |
| EBIT | $514.40M | |
| EBITDA | $654.30M | |
| Basic shares | 585.54M | |
| Diluted shares | 590.30M |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $461.10M | $264.50M | +74.3% |
| Cash & short-term investments | $461.10M | $264.50M | +74.3% |
| Accounts receivable | $291.50M | $267.30M | +9.1% |
| Inventory | $327.30M | $342.90M | -4.5% |
| Total current assets | $1.15B | $935.40M | +23.2% |
| Property, plant & equipment | $1.41B | $1.34B | +5.1% |
| Goodwill & intangibles | $72.70M | $82.10M | -11.4% |
| Total assets | $2.85B | $2.55B | +11.9% |
| Total current liabilities | $497.80M | $500.40M | -0.5% |
| Current debt | $7.30M | $64.00M | -88.6% |
| Long-term debt | $52.50M | — | — |
| Total debt | $146.10M | $153.30M | -4.7% |
| Total liabilities | $738.20M | $660.40M | +11.8% |
| Retained earnings | $1.44B | $1.23B | +17.6% |
| Shareholder equity | $2.12B | $1.89B | +11.9% |
| Working capital | $654.40M | $435.00M | +50.4% |
| Net tangible assets | $2.04B | $1.81B | +13.0% |
| Shares issued | 587.28M | 583.54M | +0.6% |
| Line item | 2025-03-31 | YoY |
|---|---|---|
| Capital expenditure | -$103.00M | |
| Investing cash flow | -$103.00M | |
| Dividends paid | -$195.90M | |
| Financing cash flow | -$268.20M | |
| Free cash flow | $445.60M | |
| End cash position | $260.20M |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $2.55B | +10.3% |
| Next year | — | — | $2.85B | +11.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders3.65%
Held by institutions38.13%
Institutions holding281
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
24.07
+2.01% from price
SMA 20
23.51
+7.64% from price
SMA 50
23.00
+10.05% from price
SMA 100
22.59
+8.66% from price
SMA 200
22.30
+13.49% from price
EMA 12
24.18
+1.54% from price
EMA 26
23.59
+4.07% from price
EMA 50
23.14
+6.10% from price
RSI (14)
99.2
Overbought
MACD (12,26,9)
0.59
Hist 0.22
ATR (14)
0.17
0.66% of price
Realised vol 30D
21.0%
Annualised
Bollinger upper
25.25
20, 2σ
Bollinger lower
21.78
20, 2σ
50 / 200 cross
Golden
23.00 vs 22.30
Trend bias
Above 200
+13.49%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.08
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
21.0%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-17.8%
Peak to trough
Max drawdown 5Y
-56.8%
Peak to trough
ATR 14
0.17
0.66% of price
Beta (reported)
0.89
5Y monthly, from filing
Dividends & splits
Forward rate$0.30 / yr
Forward yield1.17%
5-year avg yield1.44%
Payout ratio54.22%
Ex-dividend dateJun 22, 2026
Next pay date—
Last split5:1
Split dateOct 4, 2004
Headlines
JA Powers Fisher & Paykel Healthcare's Green Transition with New Zealand's Largest Rooftop PV System
CNW Group · 5d ago
[Latest] Global Neonatal Infant Care Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
GlobeNewswire · 56d ago
[Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)
GlobeNewswire · 61d ago
Analyst Estimates: Here's What Brokers Think Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) After Its Full-Year Report
Simply Wall St. · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.